T
Tesseract Medical Research
Tesseract - Preventative & Nutritional Supplementation
About Tesseract Medical Research
Tesseract Medical Research, founded in 2016 by Al Czap, is a life sciences company focused on advancing health through nutraceuticals. Czap, who previously founded and led Thorne Research, established Tesseract with the goal of overcoming common obstacles in nutrient supplementation, such as low bioavailability and poor tolerance. His experience in creating pure, allergen-free formulations at Thorne set the stage for his work at Tesseract, where he continues to address the challenge of delivering beneficial molecules effectively.
The company operates in the nutraceutical and medical food markets, serving both healthcare practitioners and consumers directly. Its business model centers on the development and sale of supplements that utilize a proprietary, patent-pending nutrient delivery system. In 2023, Tesseract acquired the tolling and operations business from Pulse Combustion Systems, a move intended to give it greater control over its manufacturing processes, which are crucial for its core business. This vertical integration reflects a strategy to manage and scale the production of its specialized products.
Tesseract's core offering is its advanced delivery technology, which enhances the absorption of active ingredients. This system involves a two-step process named CyLoc® and DexKey®. First, the CyLoc® technology encases individual molecules of an ingredient in a dextrin fiber matrix, protecting them through the digestive system and masking any unpalatable taste or odor. Then, the DexKey® process facilitates the release of the active ingredient at the desired point in the intestinal tract for optimal absorption. This allows for lower, more effective doses, a concept the company refers to as micro-dosing. Products incorporating this technology include ProButyrate® for gastrointestinal health, QuerciSorb™ for immune response, and AuRx®, a medical food developed for individuals on the Autism Spectrum.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Jun 2024 | $20M | $80M | Geding Venture Capital · Chengwei Capital · Curie.Bio | ↗ |
Growth signals
Latest recorded traffic for Tesseract Medical Research is 4.9K monthly website visits, up 28.9% over the last three months. Tesseract Medical Research's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tesseract Medical Research in the Napa ecosystem
The Tesseract Medical Research office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
- GCGeding Venture Capital
Chengwei Capital
Curie.Bio
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tesseract Medical Research on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tesseract Medical Research’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









